ABBV AbbVie Inc.

78.52
+0.95  (+1%)
Previous Close 77.57
Open 77.6
Price To Book -13.75
Market Cap 116065493736
Shares 1,478,164,719
Volume 2,048,210
Short Ratio 3.75
Av. Daily Volume 5,592,140

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
Risankizumab
Ulcerative colitis
Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-414
Recurrent glioblastoma (rGBM)
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Alzheimer's disease
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Partial clinical hold announced March 19, 2019.
Venetoclax
Relapsed or refractory multiple myeloma
Phase 3 trial planned.
Venclexta
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial planned.
Venclexta
Follicular lymphoma (FL)
Phase 3 trial to commence 2H 2017.
Risankizumab
Crohn’s Disease
BLA filing announced April 25, 2018. PDUFA estimate April 24, 2019.
Risankizumab
Psoriasis
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Phase 3 trial to commenced 2017.
ABT-494
Psoriatic Arthritis
Phase 3 trial planned for 2018.
Risankizumab
Psoriatic Arthritis
Phase 3 trial initiated late 2017.
ABT-494
Crohn’s Disease
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
ABT-494
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
NDA filing due 2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
PDUFA date under priority review estimated at August 19, 2019.
ABT-494 upadacitinib
Rheumatoid arthritis
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3 data due 2020.
Rova-T (MERU)
First-line Small Cell Lung Cancer
FDA approval announced January 28, 2019.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
sNDA filing announced March 7, 2018.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
Phase 3 primary endpoint not met (PFS/OS).
Ibrutinib (Imbruvica)
Pancreatic cancer
Phase 3 data to be presented at ASCO June 2019.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma